Our Services

Pediatric epilepsy

Pediatric epilepsy

Marcelo Lancman, MD, and Eric Segal, M.D.

Medical Staff:
Lorraine M. Lazar, M.D., Ph.D.
José Serruya, MD
Firas Taha, M.D.
Belinda Oyinkan Marquis, MD
Rajeshwari Mahalingam, MD
Don Mathew, MD

Program Description:
• Our Pediatric Epilepsy Program specializes in evaluating and treating children with epilepsy and seizures. Our health care professionals understand that a child with epilepsy and his or her family encounter special challenges that often require a team of professionals.  This team includes child neurologists with specialty training in epilepsy neurosurgeons, a psychiatristnurses, and neuropsychologists. Our Pediatric Epilepsy team is multidisciplinary in order to simultaneously provide exceptional medical care, psychological support, educational assistance, and social and community activities. Our pediatric epilepsy program works closely with local epilepsy foundations and Epilepsy America Alliance assisting our patients to gain access to the many important resources they provide.

• Specialty programs:
* Medical treatment programs
   - Approved seizure medications
   - Experimental seizures medications (not available on the market)
* Surgical treatment program
* Tuberous Sclerosis Specialty Center
* Dravet Syndrome Specialty Center
* Sturge-Weber Specialty Center

Open Research Studies:
- A Multicenter, Randomized, double-blind, parallel group, placebo- controlled trial of two fixed doses of ZX008 (Fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome.

1042-0900: A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Extension

An Open-Label, Multicenter study with an Extension Phase to Evaluate the Safety , Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral suspension when Administered as an Adjunctive Therapy in pediatric Subjects (Age 4 to less than 12years) with inadequately Controlled Partial-Onset Seizures or Primary generalized Tonic-Clonic seizures

- A randomized, double-blind, placebo- controlled study to investigate the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet Syndrome

Our physicians' scientific publications:

Akman CI, Abou Khaled KJ, Segal E, Micic V, Riviello JJ. Generalized periodic epileptiform discharges in critically ill children: clinical features, and outcome. Epilepsy Res. 2013;106(3):378-385. doi:10.1016/j.eplepsyres.2013.06.019 

- Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018;59(8):1540-1548. doi:10.1111/epi.14477

- Helbig KL, Lauerer RJ, Bahr JC, et al. De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias [published correction appears in Am J Hum Genet. 2019 Mar 7;104(3):562]. Am J Hum Genet. 2018;103(5):666-678. doi:10.1016/j.ajhg.2018.09.006

- Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20. doi:10.1016/j.eplepsyres.2019.03.015

- Kornitzer J, Taha F, Segal E. Clinical Presentation and Outcome in Autoimmune Encephalitis Associated With N-Type Voltage-Gated Calcium Channels in Children. J Child Neurol. 2019;34(9):499-505. doi:10.1177/0883073819840448

- Myers L, Trobliger R, Bortnik K, Zeng R, Segal E, Lancman M. Dissociation and other clinical phenomena in youth with psychogenic non-epileptic seizures (PNES) compared to youth with epilepsy. Seizure. 2019;70:49-55. doi:10.1016/j.seizure.2019.06.028

- Hogan RE, Tarquinio D, Sperling MR, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. Epilepsia. 2020;61(5):935-943. doi:10.1111/epi.16506

- Szaflarski M, McGoldrick P, Currens L, et al. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists. Epilepsy Behav. 2020;109:107102. doi:10.1016/j.yebeh.2020.107102

- Gibbs SN, Choi J, Khilfeh I, Ahmed KH, Yermilov I, Segal E. The Humanistic and Economic Burden of Pediatric Focal Seizures in the United States. J Child Neurol. 2020;35(8):543-555. doi:10.1177/0883073820911785

- Gupta S, Schwab M, Valdez-Gonzalez K, Segal E. Rare homozygous nonsense variant in AIMP1 causing Early Onset Epileptic Encephalopathy with Burst Suppression (EOEE-BS). Eur J Med Genet. 2020;63(9):103970. doi:10.1016/j.ejmg.2020.103970

- Tomycz L, Hale AT, Abdulrazeq HF, Naftel RP, Englot DJ, Segal E. An algorithmic approach to preoperative studies and patient selection for hemispheric disconnection surgery: a literature review. An algorithmic approach to preoperative studies and patient selection for hemispheric disconnection surgery: a literature review. Epileptic Disord. 2020;22(5):592-609. doi:10.1684/epd.2020.1205

- Miller I, Wheless JW, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D. Consistent safety and tolerability of Valtoco®(diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study. Epilepsia Open. 2021 May 5.

- Segal EB, Tarquinio D, Miller I, Wheless JW, Dlugos D, Biton V, Cascino GD, Desai J, Hogan RE, Liow K, Sperling MR. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long‐term, open‐label safety study. Epilepsia. 2021 Jun;62(6):1442-50.

- Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D. Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021 Oct;62(10):2485-95.

- Sabeti S, Ball KL, Bhattacharya SK, Bitrian E, Blieden LS, Brandt JD, Burkhart C, Chugani HT, Falchek SJ, Jain BG, Juhasz C. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. Pediatric Neurology. 2021 May 6.

- Segal, Eric, et al. "PROVE—Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Interim Analysis in Pediatric Patients." Journal of Child Neurology 37.4 (2022): 256-267.

- Segal, Eric, et al. "Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study." Seizure 98 (2022): 87-94.

- Peters, J. M., Puri, V., Segal, E., Misra, S. N., Rabinowicz, A. L., & Carrazana, E. (2023). Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. Epilepsy & Behavior, 144, 109248. 

- Flamini, R. J., Comi, A. M., Bebin, E. M., Chez, M. G., Clark, G., Devinsky, O., ... & Weinstock, A. (2023). Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the expanded access program. Epilepsia.

- Tarquinio, D., Wheless, J. W., Segal, E. B., Misra, S. N., Rabinowicz, A. L., & Carrazana, E. (2023). Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study. Journal of Child Neurology, 08830738231185424.

- Wechsler, R. T., Wheless, J., Zafar, M., Huesmann, G. R., Lancman, M., Segal, E., ... & Malhotra, M. (2022). PROVE: Retrospective, non‐interventional, Phase IV study of perampanel in real‐world clinical care of patients with epilepsy. Epilepsia open, 7(2), 293-305.

- Braun, E., Gualano, F. M., Siddarth, P., & Segal, E. (2023). Second-line cannabis therapy in patients with epilepsy. Clinical Neurology and Neurosurgery, 107638.

- Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory Epilepsy

Effect of treatment of obstructive sleep apnea on seizure outcomes in children with epilepsy

- Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy

- Chorea associated with antiphospholipid antibodies in a patient with Kabuki syndrome

- Seizures from valproate-carbapenem interaction

- Clinically significant bradyarrhythmias in video-EEG patients

Lazar, L.M., Milrod, L.M., Solomon, G.E., Labar, D.R. Asynchronous pentobarbital-induced burst suppression with corpus callosum hemorrhage. Clin Neurophysiol 1999; 110(6): 1036-40.

- Harden, C.L., Lazar, L.M., Pick, L.H., Nikolov, B., Goldstein, M.A., Ravdin, L.D., Kocsis, J.H., Labar, D.R. A beneficial effect on mood in partial epilepsy patients treated with gabapentin.  Epilepsia 1999; 40(8): 1129-34.

- Trifiletti, R.R., Lazar, L.M., Bojko, A., Chutorian, A.M., DiMauro, S. Early poliodystrophy with mitochondrial defect: two cases.  Child Neurology Society Abstr 1996: 59. (Presented at the 25th annual meeting of the Child Neurology Society, Minneapolis, Minnesota)

- Lazar, L.M., Blum, M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay.  J Neurosci 1992; 12(5): 1688-1697.

- Lazar, L.M. Epidermal growth factor and transforming growth factor-alpha gene expression in the normal and neurodegenerate murine central nervous system.  Doctoral dissertation 1992; Mount Sinai School of Medicine of the City University of New York.

- Lazar, L.M., Kelley, K.A., Blum, M. Epidermal growth factor and transforming growth factor-alpha mRNA expression in Purkinje Cell Degeneration and weaver mutant mice.  Soc Neurosci Abstr 1990; 16:999.  (Presented at the 20th annual meeting of the Society for Neuroscience, St. Louis, MO)


To make an appointment: (914) 428-9213 or 201-343-6676